Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review

To the Editor: Halobetasol propionate 0.01%/tazarotene 0.045% lotion (HP/TAZ) was developed as an effective, safe, and tolerable topical therapy for plaque psoriasis. It has been investigated in moderate-to-severe plaque psoriasis1Sugarman J.L. Gold L.S. Lebwohl M.G. Pariser D.M. Alexander B.J. Pillai R. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis.J Drugs Dermatol. 2017; 16: 197-204PubMed Google Scholar, 2Gold L.S. Lebwohl M.G. Sugarman J.L. et al.Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials.J Am Acad Dermatol. 2018; 79: 287-293Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 3Sugarman J.L. Weiss J. Tanghetti E.A. et al.Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies.J Drugs Dermatol. 2018; 17: 855-861PubMed Google Scholar; however, real-world data on the use of topical fixed-combination therapies for plaque psoriasis, particularly milder disease courses, are limited. In a pooled analysis of phase 3 studies involving patients with moderate-to-severe plaque psoriasis (baseline Investigator Global Assessment [IGA] score of 3/4 and affected body surface area [BSA] of 3%-12%),2Gold L.S. Lebwohl M.G. Sugarman J.L. et al.Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials.J Am Acad Dermatol. 2018; 79: 287-293Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar,3Sugarman J.L. Weiss J. Tanghetti E.A. et al.Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies.J Drugs Dermatol. 2018; 17: 855-861PubMed Google Scholar 40.6% of HP/TAZ-treated patients versus 9.9% of vehicle-treated patients achieved treatment success (IGA score of clear/almost clear [0/1] with ≥2-grade improvement from baseline) by week 8 (P < .001). HP/TAZ was also more effective than vehicle in reducing affected BSA (mean reduction: 37.6% vs 3.1%; P < .001).1Sugarman J.L. Gold L.S. Lebwohl M.G. Pariser D.M. Alexander B.J. Pillai R. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis.J Drugs Dermatol. 2017; 16: 197-204PubMed Google Scholar We conducted a Canadian multicenter retrospective chart review of 109 patients with mild-to-moderate plaque psoriasis defined as ≤7% BSA (as 5%-10% BSA is appropriate for defining moderate psoriasis).4Llamas-Velasco M. de la Cueva P. Notario J. Martínez-Pilar L. Martorell A. Moreno-Ramírez D. Moderate psoriasis: a proposed definition.Actas Dermosifiliogr. 2017; 108: 911-917Crossref PubMed Scopus (39) Google Scholar Patients with involvement of the face, intertriginous areas, and/or genitals were excluded. Eligible patients had initiated HP/TAZ (dosed in accordance with its product label) as monotherapy or as an adjunct to a stable dose of systemic therapy (ST) for ≥3 months. Patients using other topical medications were not excluded. The primary end point was the proportion of patients achieving treatment success (described above). The efficacy results reported herein are for week 8. Most patients (95/109; 87.2%) maintained a stable dose of ST and/or HP/TAZ and completed 8 weeks of treatment (Table I). Overall, 43 of 95 (45.3%) patients achieved treatment success, which aligns with HP/TAZ in moderate-to-severe plaque psoriasis.2Gold L.S. Lebwohl M.G. Sugarman J.L. et al.Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials.J Am Acad Dermatol. 2018; 79: 287-293Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar,3Sugarman J.L. Weiss J. Tanghetti E.A. et al.Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies.J Drugs Dermatol. 2018; 17: 855-861PubMed Google Scholar A numerically higher proportion of patients receiving HP/TAZ monotherapy than HP/TAZ+ST achieved treatment success (33/58 [56.9%] vs 10/37 [27.0%]). IGA 0/1 was achieved by 63/95 (66.3%) of the overall population, with similar findings observed in the treatment subgroups (Fig 1). The absolute Psoriasis Area and Severity Index scores were lowered by 2.4 ± 1.6 (overall), 2.5 ± 1.7 (HP/TAZ monotherapy), and 2.1 ± 1.3 (HP/TAZ+ST), whereas the mean affected BSA was reduced by 47.8%, 56.7%, and 36.5%, respectively. For patients with scalp involvement (19/109 [17.4%])—the most common difficult-to-treat site5Egeberg A. See K. Garrelts A. Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort.BMC Dermatol. 2020; 20: 3Crossref PubMed Scopus (27) Google Scholar—13/17 (76.5%), 10/15 (66.7%), and 2/2 (100%), respectively, achieved treatment success, whereas the mean affected BSA reduction was consistently high across the treatment groups (Table I).Table IEfficacy, safety, and demographic and clinical characteristics of patients with mild-to-moderate plaque psoriasis treated with HP/TAZVariableOverall n = 109HP/TAZ M n = 67HP/TAZ+ST n = 42∗Systemic nonbiologic therapies used by patients were acitretin (n = 3) and apremilast (n = 3).†Systemic biologic therapies used by patients were adalimumab (n = 2), brodalumab (n = 1), certolizumab pegol (n = 1), etanercept (n = 2), guselkumab (n = 5), ixekizumab (n = 6), risankizumab (n = 5), secukinumab (n = 5), and ustekinumab (n = 9).Age, y; mean ± SD49.7 ± 15.848.6 ± 17.451.4 ± 12.6Sex, n (%): Female51 (46.8)29 (43.3)22 (52.4) Male58 (53.2)38 (56.7)20 (47.6)Sites of involvement, n (%): Lower limbs77 (70.6)52 (77.6)25 (59.5) Upper limbs71 (65.1)49 (73.1)23 (54.8) Trunk35 (32.1)21 (31.3)15 (35.7) Head and neck28 (26.7)17 (25.4)11 (26.2) Special site: scalp27 (24.8)16 (23.9)11 (26.2) Special site: palmoplantar8 (7.3)4 (6.0)4 (9.5)Prior topical therapies, n (%): None5 (4.6)5 (7.5)0 133 (30.3)15 (22.4)18 (42.9) 227 (24.8)19 (28.4)8 (19.0) 3+44 (40.4)28 (41.8)16 (38.1)Prior systemic therapy, n (%): None67 (61.5)67 (100)NA Nonbiologic∗Systemic nonbiologic therapies used by patients were acitretin (n = 3) and apremilast (n = 3).6 (5.5)NA6 (14.3) Biologic†Systemic biologic therapies used by patients were adalimumab (n = 2), brodalumab (n = 1), certolizumab pegol (n = 1), etanercept (n = 2), guselkumab (n = 5), ixekizumab (n = 6), risankizumab (n = 5), secukinumab (n = 5), and ustekinumab (n = 9).36 (33.0)NA36 (85.7)Overall population: all patients, regardless of the site of involvementBaseline disease characteristics Affected BSA (%), mean ± SD3.2 ± 1.73.5 ± 1.42.9 ± 1.9 PASI score, mean ± SD‡Baseline PASI scores were available for 70 patients in the overall population, 60 patients in the HP/TAZ M group, and 10 patients in the HP/TAZ+ST group.4.1 ± 1.94.3 ± 1.93.0 ± 1.3 IGA score, n (%):110 (9.2)1 (1.5)9 (21.4)231 (28.4)12 (17.9)19 (45.2)368 (62.4)54 (80.6)14 (33.3)Efficacy at week 8 Affected BSA (%), mean ± SD§Week 8 affected BSA was available for 95 patients in the overall population, 58 patients in the HP/TAZ M group, and 37 patients in the HP/TAZ+ST group.1.8 ± 1.81.6 ± 1.42.1 ± 2.2 PASI score, mean ± SD‖Week 8 PASI score was available for 60 patients in the overall population, 52 patients in the HP/TAZ M group, and 8 patients in the HP/TAZ+ST group.1.8 ± 1.61.9 ± 1.61.0 ± 0.7 IGA score, n/N (%):019/95 (20.0)14/58 (24.1)5/37 (13.5)144/95 (46.3)23/58 (39.7)21/37 (56.8)225/95 (26.3)17/58 (29.3)8/37 (21.6)35/95 (5.3)4/58 (6.9)1/37 (2.7)42/95 (2.1)02/37 (5.4)Treatment satisfaction at week 8, mean ± SD¶Treatment satisfaction with HP/TAZ was captured on a 10-point scale where “1 = least satisfied” and “’10 = most satisfied.” Data were available for 98 patients in the overall population, 59 patients in the HP/TAZ M group, and 39 patients in the HP/TAZ+ST group.6.6 ± 2.96.7 ± 2.96.4 ± 2.8Adverse events leading to discontinuation up to week 8, n (%)12 (11.1)9 (13.4)3 (7.1)Subpopulation: patients with scalp involvementBaseline disease characteristics Affected BSA (%), mean ± SD#Baseline affected BSA and baseline IGA were available for 19 patients in the overall population, 15 patients in the HP/TAZ M group, and 4 patients in the HP/TAZ+ST group.1.2 ± 0.81.2 ± 0.91.3 ± 0.6 IGA score, n/N (%)#Baseline affected BSA and baseline IGA were available for 19 patients in the overall population, 15 patients in the HP/TAZ M group, and 4 patients in the HP/TAZ+ST group.10/19 (0)0/15 (0)0/4 (0)23/19 (15.8)2/15 (13.3)1/4 (25.0)316/19 (84.2)13/15 (86.7)3/4 (75.0)Efficacy at week 8 Affected BSA (%), mean ± SDWeek 8 affected BSA and Week 8 IGA were available for 17 patients in the overall population, 15 patients in the HP/TAZ M group, and 2 patients in the HP/TAZ+ST group.0.4 ± 0.40.4 ± 0.40.5 ± 0.5 IGA score, n/N (%)Week 8 affected BSA and Week 8 IGA were available for 17 patients in the overall population, 15 patients in the HP/TAZ M group, and 2 patients in the HP/TAZ+ST group.08/17 (47.1)7/15 (46.7)1/2 (50.0)15/17 (29.4)4/15 (26.7)1/2 (50.0)24/17 (23.5)4/15 (26.7)0Safety in the overall populationTreatment-related AEs during 8 wks of treatment, n (%) Any AE42 (38.5)30 (44.8)12 (28.6) Irritation35 (32.1)28 (41.8)7 (16.7) Erythema19 (17.4)11 (16.4)8 (19.0) Burning16 (14.7)15 (22.4)1 (2.4) Pain14 (12.8)10 (14.9)4 (19.5) Pruritus12 (11.0)10 (14.9)2 (4.8) Atrophy000 Hypopigmentation000AE, Adverse event; BSA, body surface area; HP/TAZ, halobetasol propionate 0.01%/tazarotene 0.045% lotion; IGA, Investigator Global Assessment; M, monotherapy; NA, not applicable; PASI, Psoriasis Area and Severity Index; ST, systemic therapy.∗ Systemic nonbiologic therapies used by patients were acitretin (n = 3) and apremilast (n = 3).† Systemic biologic therapies used by patients were adalimumab (n = 2), brodalumab (n = 1), certolizumab pegol (n = 1), etanercept (n = 2), guselkumab (n = 5), ixekizumab (n = 6), risankizumab (n = 5), secukinumab (n = 5), and ustekinumab (n = 9).‡ Baseline PASI scores were available for 70 patients in the overall population, 60 patients in the HP/TAZ M group, and 10 patients in the HP/TAZ+ST group.§ Week 8 affected BSA was available for 95 patients in the overall population, 58 patients in the HP/TAZ M group, and 37 patients in the HP/TAZ+ST group.‖ Week 8 PASI score was available for 60 patients in the overall population, 52 patients in the HP/TAZ M group, and 8 patients in the HP/TAZ+ST group.¶ Treatment satisfaction with HP/TAZ was captured on a 10-point scale where “1 = least satisfied” and “’10 = most satisfied.” Data were available for 98 patients in the overall population, 59 patients in the HP/TAZ M group, and 39 patients in the HP/TAZ+ST group.# Baseline affected BSA and baseline IGA were available for 19 patients in the overall population, 15 patients in the HP/TAZ M group, and 4 patients in the HP/TAZ+ST group.∗∗ Week 8 affected BSA and Week 8 IGA were available for 17 patients in the overall population, 15 patients in the HP/TAZ M group, and 2 patients in the HP/TAZ+ST group. Open table in a new tab AE, Adverse event; BSA, body surface area; HP/TAZ, halobetasol propionate 0.01%/tazarotene 0.045% lotion; IGA, Investigator Global Assessment; M, monotherapy; NA, not applicable; PASI, Psoriasis Area and Severity Index; ST, systemic therapy. The most common adverse events occurring up to week 8 were irritation (32.1%), erythema (17.4%), and burning (14.7%). There were no cases of atrophy (rare in clinical studies1Sugarman J.L. Gold L.S. Lebwohl M.G. Pariser D.M. Alexander B.J. Pillai R. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis.J Drugs Dermatol. 2017; 16: 197-204PubMed Google Scholar, 2Gold L.S. Lebwohl M.G. Sugarman J.L. et al.Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials.J Am Acad Dermatol. 2018; 79: 287-293Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 3Sugarman J.L. Weiss J. Tanghetti E.A. et al.Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies.J Drugs Dermatol. 2018; 17: 855-861PubMed Google Scholar) or hypopigmentation. Discontinuation because of adverse events (11.1%) was somewhat higher than that reported in phase 3 studies (6.3%).3Sugarman J.L. Weiss J. Tanghetti E.A. et al.Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies.J Drugs Dermatol. 2018; 17: 855-861PubMed Google Scholar Two patients receiving HP/TAZ+ST experienced worsening in the IGA score (1 case each of 1-grade and 2-grade worsening); the patient with 2-grade worsening subsequently discontinued the treatment. Overall, patients expressed moderate treatment satisfaction with HP/TAZ (mean rating: 6.6/10; Table I). Despite the limitations commonly associated with retrospective chart reviews (eg, sampling size/bias, methodological constraints), collectively, this real-world analysis of HP/TAZ in Canadian patients with mild-to-moderate plaque psoriasis suggests that it is an effective, safe, and satisfactory treatment. This warrants large and prospective real-world studies in this patient population. Dr Vender has served as a consultant, investigator, and/or received support or honoraria from AbbVie, Actelion, Amgen, Aralez, Arcutis, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Cipher, Janssen, Galderma, GSK, Kabi-Care, Leo, Lilly, Merck, Novartis, Palladin, Pfizer, Sandoz, Sun Pharma, UCB, and Viatris-Mylan. Dr Turchin has served as consultant, speaker, or investigator for AbbVie, Amgen, Arcutis, Aristea, Bausch Health, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, Kiniksa, LeoPharma, Mallinckrodt, Novartis, Pfizer, Sanofi, Sun Pharma, and UCB. Dr Lansang has received honoraria and consulting fees from AbbVie, Amgen, Bausch, Celgene, Galderma, Janssen, Lilly, Novartis, Pfizer, Sanofi, UCB, and Valeant. Dr Prajapati has served as an investigator for AbbVie, Amgen, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Nimbus Lakshmi, Novartis, Pfizer, Regeneron, Reistone, Sanofi Genzyme, UCB, and Valeant and has served as a consultant, advisor, and/or speaker for AbbVie, Actelion, Amgen, Aralez, Arcutis, Aspen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Janssen, LEO Pharma, L'Oreal, Medexus, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant. Dr Legault is an employee of Bausch Health Canada. Dr Barakat is an employee of Bausch Health Canada. Dr Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Bausch Health, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.